Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C29H23F6N5O3 |
Molecular Weight | 603.515 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CN=C3C[C@]4(CC3=C2)C(=O)NC5=C4C=CC=N5)C(=O)N1CC(F)(F)F)C6=C(F)C(F)=CC=C6F
InChI
InChIKey=QIVUCLWGARAQIO-OLIXTKCUSA-N
InChI=1S/C29H23F6N5O3/c1-13-16(22-18(30)4-5-19(31)23(22)32)8-20(26(42)40(13)12-29(33,34)35)38-25(41)15-7-14-9-28(10-21(14)37-11-15)17-3-2-6-36-24(17)39-27(28)43/h2-7,11,13,16,20H,8-10,12H2,1H3,(H,38,41)(H,36,39,43)/t13-,16-,20+,28+/m1/s1
Molecular Formula | C29H23F6N5O3 |
Molecular Weight | 603.515 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
MK-8031 (also known as Atogepant) is piperidinonylcarboxamideazaindane derivative patented by Merck Sharp & Dohme Corp as CGRP receptor antagonist useful for prevention and treatment of Migraine. A press release in June 2018 announced positive results for MK-8031, in a Phase 2 trial of daily use for episodic migraine prevention. MK-8031appeared to show good efficacy in migraine prevention and no significant liver toxicity signal at any dose despite daily dosing for 3 months. Phase III clinical trial was initiated in 2019 and currently in progress.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT03939312
60 mg once a day
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:44:43 GMT 2023
by
admin
on
Sat Dec 16 08:44:43 GMT 2023
|
Record UNII |
7CRV8RR151
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1374248-81-3
Created by
admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023
|
PRIMARY | |||
|
72163100
Created by
admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023
|
PRIMARY | |||
|
300000011223
Created by
admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023
|
PRIMARY | |||
|
7CRV8RR151
Created by
admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023
|
PRIMARY | |||
|
10510
Created by
admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023
|
PRIMARY | |||
|
7CRV8RR151
Created by
admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023
|
PRIMARY | |||
|
EF-106
Created by
admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023
|
PRIMARY | |||
|
Atogepant
Created by
admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023
|
PRIMARY | |||
|
DTXSID901337079
Created by
admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023
|
PRIMARY | |||
|
C167018
Created by
admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023
|
PRIMARY | |||
|
2571813
Created by
admin on Sat Dec 16 08:44:43 GMT 2023 , Edited by admin on Sat Dec 16 08:44:43 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
BINDS TO RECEPTOR AND BLOCKS BINDING
|
||
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Merck & Co; Class: Piperidine, Small molecule, Spiro compound; Mechanism of Action: Calcitonin gene-related peptide receptor antagonists; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Preclinical for Migraine; Most Recent Events: 09 Jul 2015 Merck enters into an agreement with Allergan for the divestiture of MK 8031, 07 Jul 2015 Merck plans a phase II study for Migraine, 07 Jul 2015 Preclinical development is underway in USA
|